Cochlear Limited

COH

AU000000COH5

Medical Equipment, Supplies & Distribution

Market Closed - Australian S.E. Other stock markets 02:10:14 2024-06-28 EDT			5-day change	1st Jan Change
332.2 ^AUD	+1.83%		+5.44%	+11.21%

05-29	UK’s Competition Regulator Closes Cochlear-Demant Deal	MT
05-21	Cochlear Completes Acquisition of Oticon Medical's Cochlear Implant Business	MT

Cochlear Limited Provides Earnings Guidance for the Fiscal Year 2024

August 14, 2023 at 08:01 pm

Cochlear Limited provided earnings guidance for the fiscal year 2024. For the year, the company expects net profit to be between $355 million to $375 million and anticipates revenue growth.

Latest news about Cochlear Limited

UK’s Competition Regulator Closes Cochlear-Demant Deal	05-29	MT
Cochlear Completes Acquisition of Oticon Medical's Cochlear Implant Business	05-21	MT
Cochlear Limited acquired Oticon Medical A/s from Demant A/S.	05-20	CI
Cochlear Limited Announces Company Secretary Changes	04-21	CI
Cochlear Limited Receives Fda Clearance to Lower the Age for the Osia System to 5-Year-Old	04-19	CI
Competition Regulator Clears Cochlear’s Acquisition of Oticon Medical’s Cochlear Implant Business	04-03	MT
Miners, healthcare firms push Australia stocks higher	03-25	RE
Sensorion: study results in hearing loss	03-11	CF
Morgan Stanley Adjusts Cochlear’s Price Target to AU$276 From AU$258, Keeps at Underweight	03-05	MT
Jarden Research Adjusts Cochlear’s Price Target to AU$244.35 From AU$237.17, Keeps at Neutral	02-19	MT
Cochlear's Revenue Soars on Sales Growth	02-19	MT
Australian Shares Flat as Mining, Financials Rally Offset Other Sectors' Losses	02-19	MT
Cochlear Shares Slip 2%; Expects 26% Rise in Full Year Net Profit After Increase in H1 FY24 Profit, Revenue	02-18	MT
Transcript : Cochlear Limited, H1 2024 Earnings Call, Feb 19, 2024	02-18
Cochlear Posts Rise in H1 FY24 Profit, Revenue	02-18	MT
Correction: --Cochlear Reports Half Year FY24 Revenue Up 24% to AU$1.1 Billion; EPS of AU$2.913	02-18	MT
Cochlear Reports Half Year FY24 Revenue Up Down 24% to AU$1.1 Billion; EPS of AU$2.913	02-18	MT
Tranche Update on Cochlear Limited's Equity Buyback Plan announced on February 15, 2023.	02-18	CI
Cochlear Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-18	CI
Cyclopharm Appoints CFO; Shares Rise 3%	02-12	MT
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)	02-11	RE
Australian shares post first weekly fall in three as rate-hike bets back in focus	02-09	RE
Jarden Research Adjusts Cochlear's Price Target to AU$237.17 From AU$229.20, Keeps at Neutral	02-09	MT
Cochlear Upgrades Fiscal 2024 Profit Guidance; Shares Up 5%	02-07	MT
Transcript : Cochlear Limited - Analyst/Investor Day	23-10-26

Cochlear Limited is an Australia-based company, which provides implantable hearing solutions and sound processors. The Company is engaged in development, manufacture and commercialization of implantable hearing solutions. Its segments include Cochlear implants, Services (sound processor upgrades and other) and Acoustics. The Companyâs products and services portfolio include Cochlear implant portfolio, Acoustic solutions portfolio, and Recipient support tools. Its Cochlear Connected Care solutions include Cochlear Nucleus SmartNav System, Cochlear Custom Sound Pro Fitting Software, Cochlear Link, Cochlear Remote Assist, and Cochlear Remote Check solution for cochlear implants. Its Cochlear implant portfolio include Cochlear Nucleus System. Its Acoustic solutions portfolio include Cochlear Osia System, and Cochlear Baha System. Its Recipient support tools include Cochlear Nucleus, Baha and Osia Smart Apps and Cochlear CoPilot App.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-14 - Q4 2024 Earnings Release

Related indices

S&P/ASX 200

More about the company

Income Statement Evolution

More financial data

Ratings for Cochlear Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

326.2 AUD

Average target price

280.9 AUD

Spread / Average Target

-13.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Prosthetics

	1st Jan change	Capi.
COCHLEAR LIMITED	+11.21%	14.19B
SONOVA HOLDING AG	+1.17%	18.32B
DEMANT A/S	+1.82%	9.52B
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD.	-23.29%	1.95B
EMBLA MEDICAL HF.	+7.47%	1.76B
ANGELALIGN TECHNOLOGY INC.	+0.35%	1.21B
MODERN DENTAL GROUP LIMITED	0.00%	526M
ANGEL ROBOTICS CO., LTD.	0.00%	365M
DELCATH SYSTEMS, INC.	+103.85%	229M
INTEGRUM AB	+20.04%	97.49M

Medical Prosthetics